Finally, using the validated model, they explored the efficacy of and resistance to mTORC1 inhibition, with results suggesting that patients with MEN1 loss are more likely to benefit (experience control to a quiescent phenotype) compared to patients with tuberous sclerosis (TSC) or DAXX loss. This evidence concerns the gene MEN1 and tuberous sclerosis.